Table 1.
Patient characteristics at baseline.
| Characteristic | All patients (n = 13) | TNBC patients (n = 8) | OC patients (n = 5) |
|---|---|---|---|
| Age, median (range) | 50 (39-74) | 48 (39-55) | 66 (55-74) |
| ECOG performance status, No. (%) | |||
| 0 | 8 (61.5) | 5 (62.5) | 3 (60) |
| 1 | 5 (38.5) | 3 (37.5) | 2 (40) |
| Race, No. (%) | |||
| Asian | 1 (7.7) | 1 (12.5) | 0 (0) |
| Black or African American | 1 (7.7) | 0 (0) | 1 (20) |
| Caucasian or White | 10 (76.9) | 7 (87.5) | 3 (60) |
| Unknown | 1 (7.7) | 0 (0) | 1 (20) |
| Primary cancer, No. (%) | |||
| Breast | 8 (61.5) | 8 (100) | 0 (0) |
| Ovarian | 4 (30.8) | 0 (0) | 4 (80) |
| Peritoneal | 1 (7.7) | 0 (0) | 1 (20) |
| Tumor stage at diagnosis | |||
| I | 0 (0) | 0 (0) | 0 (0) |
| II | 5 (38.4) | 5 (62.5) | 0 (0) |
| III | 6 (46.15) | 1 (12.5) | 5 (100) |
| IV | 1 (7.6) | 1 (12.5) | 0 (0) |
| Unknown | 1 (7.6) | 1 (12.5) | 0 (0) |
| N stage at diagnosis | |||
| 0 | 0 (0) | 0 (0) | 1 (20) |
| 1 | 4 (30.8) | 3 (37.5) | 4 (80) |
| 2 | 2 (15.4) | 2 (25) | 0 (0) |
| 3 | 2 (15.4) | 2 (25) | 0 (0) |
| Unknown | 1 (7.6) | 1 (12.5) | 0 (0) |
| M stage at diagnosis | |||
| 0 | 6 (46.15) | 4 (50) | 2 (40) |
| 1 | 3 (23.1) | 2 (25) | 1 (20) |
| Unknown | 4 (30.8) | 2 (25) | 2 (40) |
| Prior lines of therapy, median (range) | 4 (1-6) | 5 (1-6) | 1 (1-6) |
| BRCA status, No. (%) a | |||
| g/sBRCA1/2wt | 13 (100) | 8 (100) | 5 (100) |
| g/sBRCA1/2m | 0 (0) | 0 (0) | 0 (0) |
| Homologous recombination status, No. (%) b | |||
| HRP | 6 (46) | 3 (37.5) | 3 (60) |
| HRD | 3 (23) | 2 (25) | 1 (20) |
| NA | 4 (31) | 3 (37.5) | 1 (20) |
| PD-L1 status, No. (%) c | |||
| Positive | 8 (61.5) | 5 (62.5) | 3 (60) |
| Negative | 5 (38.5) | 3 (37.5) | 2 (40) |
| No. of total cycles, median (range) | 6 (1-12) | 5 (1-12) | 11 (2-12) |
| Dose of Vigil received, % | |||
| 1 × 10e6 cells/mL | 6 (46.2) | 6 (75) | 0 (0) |
| 1 × 10e7 cells/mL | 7 (53.8) | 2 (25) | 5 (100) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HRD, homologous recombination deficient; HRP, homologous recombination proficient; NA, not available or not done; OC, ovarian cancer; PD-L1, programmed death-ligand 1; TNBC, triple-negative breast cancer.
a
BRCA status determined by Ocean Ridge Biosciences.
b
Homologous recombination status determined by Myriad myChoice CDx.
c
PD-L1 status determined by NeoGenomics Laboratories or ProPath; positivity was based on a score ⩾1% assessed by immunohistochemistry.